3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Leiomyosarcoma
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Histiocytoma, Malignant Fibrous
1
Hereditary leiomyomatosis and renal cell cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Interventions
Cyclophosphamide
26
fludarabine
18
Dexamethasone
17
pembrolizumab
12
Rituximab
12
Etoposide
10
venetoclax
9
pomalidomide
9
Gemcitabine
9
Lenalidomide
8
fludarabine phosphate
7
daratumumab
7
carfilzomib
7
Bortezomib
7
Nivolumab
6
obinutuzumab
5
glofitamab
5
Vincristine
5
Temozolomide
5
Prednisone
5
Immunotherapy, Adoptive
5
Cisplatin
5
Calcium Dobesilate
5
selinexor
4
cemiplimab
4
Doxorubicin
4
Cytarabine
4
Carboplatin
4
zanubrutinib
3
trastuzumab deruxtecan
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Recurrence
×
Erlotinib Hydrochloride
×
90 days
×
Clear all
No trials found.